{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T16:33:09Z","timestamp":1785342789058,"version":"3.55.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1124\/dmd.114.059105","type":"journal-article","created":{"date-parts":[[2014,11,21]],"date-time":"2014-11-21T00:43:18Z","timestamp":1416530598000},"page":"235-247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":138,"title":["Investigation of the Impact of Substrate Selection on In Vitro Organic Anion Transporting Polypeptide 1B1 Inhibition Profiles for the Prediction of Drug-Drug Interactions"],"prefix":"10.1016","volume":"43","author":[{"given":"Saki","family":"Izumi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitane","family":"Nozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9174-5213","authenticated-orcid":false,"given":"Kazuya","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Komori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Takenaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3641-8746","authenticated-orcid":false,"given":"Hiroyuki","family":"Kusuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.114.059105_bib1","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1124\/dmd.110.032268","article-title":"Cyclosporine A, but not tacrolimus, shows relevant inhibition of organic anion-transporting protein 1B1-mediated transport of atorvastatin","volume":"38","author":"Amundsen","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.059105_bib2","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1046\/j.1523-1755.2000.00838.x","article-title":"Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A","volume":"57","author":"Binet","year":"2000","journal-title":"Kidney Int"},{"key":"10.1124\/dmd.114.059105_bib3","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/00003088-200140050-00002","article-title":"Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials","volume":"40","author":"Burman","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.114.059105_bib4","series-title":"Drug Interaction Studies\u2014Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations: Draft Guidance","year":"2012"},{"key":"10.1124\/dmd.114.059105_bib5","series-title":"Guideline on the Investigation of Drug Interactions","year":"2012"},{"key":"10.1124\/dmd.114.059105_bib6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"Giacomini","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/dmd.114.059105_bib7","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1124\/jpet.104.068056","article-title":"Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans","volume":"311","author":"Hirano","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.114.059105_bib8","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1053\/j.gastro.2006.02.034","article-title":"Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics","volume":"130","author":"Ho","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1124\/dmd.114.059105_bib9","doi-asserted-by":"crossref","first-page":"37161","DOI":"10.1074\/jbc.274.52.37161","article-title":"A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters","volume":"274","author":"Hsiang","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.114.059105_bib10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/clpt.2010.232","article-title":"Prediction of fluoroquinolone-induced elevation in serum creatinine levels: a case of drug-endogenous substance interaction involving the inhibition of renal secretion","volume":"89","author":"Imamura","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.114.059105_bib11","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0031-6997(24)01372-3","article-title":"Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver","volume":"50","author":"Ito","year":"1998","journal-title":"Pharmacol Rev"},{"key":"10.1124\/dmd.114.059105_bib12","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1124\/dmd.113.052290","article-title":"Substrate-dependent inhibition of organic anion transporting polypeptide 1B1: comparative analysis with prototypical probe substrates estradiol-17\u03b2-glucuronide, estrone-3-sulfate, and sulfobromophthalein","volume":"41","author":"Izumi","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.059105_bib13","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/01.fpc.0000170913.73780.5f","article-title":"Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells","volume":"15","author":"Kameyama","year":"2005","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/dmd.114.059105_bib14","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11095-011-0564-9","article-title":"In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions","volume":"29","author":"Karlgren","year":"2012","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.114.059105_bib15","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1124\/dmd.108.021410","article-title":"Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin","volume":"36","author":"Kitamura","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.059105_bib16","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1124\/dmd.112.049460","article-title":"Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes","volume":"41","author":"Kudo","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.059105_bib17","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1124\/dmd.112.048330","article-title":"Effect of coadministration of single and multiple doses of rifampicin on the pharmacokinetics of fexofenadine enantiomers in healthy subjects","volume":"41","author":"Kusuhara","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.059105_bib18","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/sj.clpt.6100038","article-title":"effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers","volume":"81","author":"Lau","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.114.059105_bib19","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.2042-7158.1982.tb06206.x","article-title":"Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood","volume":"34","author":"Lemaire","year":"1982","journal-title":"J Pharm Pharmacol"},{"key":"10.1124\/dmd.114.059105_bib20","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy\u2014a genomewide study","volume":"359","author":"Link","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.114.059105_bib21","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/clpt.2011.142","article-title":"Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study","volume":"90","author":"Maeda","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.114.059105_bib22","unstructured":"Ministry of Health, Labour and Welfare (2014) Drug Interaction Guideline for Drug Development and Provision of Appropriate Information (draft). In Japanese. http:\/\/www.nihs.go.jp\/mhlw\/20131488.pdf"},{"key":"10.1124\/dmd.114.059105_bib23","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1124\/pr.55.3.1","article-title":"Impact of drug transporter studies on drug discovery and development","volume":"55","author":"Mizuno","year":"2003","journal-title":"Pharmacol Rev"},{"key":"10.1124\/dmd.114.059105_bib24","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0009-9236(99)70104-9","article-title":"Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients","volume":"65","author":"M\u00fcck","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.114.059105_bib25","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1124\/pr.110.002857","article-title":"Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake","volume":"63","author":"Niemi","year":"2011","journal-title":"Pharmacol Rev"},{"key":"10.1124\/dmd.114.059105_bib26","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1124\/dmd.106.012930","article-title":"Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3","volume":"35","author":"No\u00e9","year":"2007","journal-title":"Drug Metab Dispos"},{"issue":"Suppl 2","key":"10.1124\/dmd.114.059105_bib27","first-page":"11","article-title":"The metabolism of gemfibrozil","volume":"69","author":"Okerholm","year":"1976","journal-title":"Proc R Soc Med"},{"key":"10.1124\/dmd.114.059105_bib28","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s10928-009-9139-3","article-title":"Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data","volume":"36","author":"Poirier","year":"2009","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1124\/dmd.114.059105_bib29","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/bcp.12377","article-title":"Pitavastatin is a more sensitive and selective OATP1B clinical probe than rosuvastatin","volume":"78","author":"Prueksaritanont","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.114.059105_bib30","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ejps.2012.04.003","article-title":"Prediction of the in vivo OATP1B1-mediated drug-drug interaction potential of an investigational drug against a range of statins","volume":"47","author":"Sharma","year":"2012","journal-title":"Eur J Pharm Sci"},{"key":"10.1124\/dmd.114.059105_bib31","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1124\/jpet.112.200691","article-title":"Cynomolgus monkey as a potential model to assess drug interactions involving hepatic organic anion transporting polypeptides: in vitro, in vivo, and in vitro-to-in vivo extrapolation","volume":"344","author":"Shen","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.114.059105_bib50","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1124\/jpet.102.041921","article-title":"Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A","volume":"304","author":"Shitara","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.114.059105_bib32","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1124\/jpet.104.068536","volume":"311","author":"Shitara","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.114.059105_bib33","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1146\/annurev.pharmtox.44.101802.121444","article-title":"Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs","volume":"45","author":"Shitara","year":"2005","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/dmd.114.059105_bib34","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.pharmthera.2006.03.003","article-title":"Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions","volume":"112","author":"Shitara","year":"2006","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.114.059105_bib35","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1002\/jps.23477","article-title":"Long-lasting inhibitory effects of saquinavir and ritonavir on OATP1B1-mediated uptake","volume":"102","author":"Shitara","year":"2013","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.114.059105_bib36","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/bdd.1823","article-title":"Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption","volume":"34","author":"Shitara","year":"2013","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/dmd.114.059105_bib37","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.clpt.2004.03.010","article-title":"Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine","volume":"76","author":"Simonson","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.114.059105_bib38","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1124\/dmd.111.042382","article-title":"The development, characterization, and application of an OATP1B1 inhibition assay in drug discovery","volume":"40","author":"Soars","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.059105_bib39","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.2042-7158.2011.01389.x","article-title":"Contribution of organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 to hepatic uptake of nateglinide, and the prediction of drug-drug interactions via these transporters","volume":"64","author":"Takanohashi","year":"2012","journal-title":"J Pharm Pharmacol"},{"key":"10.1124\/dmd.114.059105_bib40","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2967\/jnumed.111.098681","article-title":"PET imaging-based evaluation of hepatobiliary transport in humans with (15R)-11C-TIC-Me","volume":"53","author":"Takashima","year":"2012","journal-title":"J Nucl Med"},{"key":"10.1124\/dmd.114.059105_bib41","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/clpt.2008.34","article-title":"The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo","volume":"84","author":"Tornio","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.114.059105_bib42","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1124\/dmd.106.013615","article-title":"Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil","volume":"35","author":"Treiber","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.059105_bib43","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1124\/dmd.112.049023","article-title":"Drug-drug interactions between rosuvastatin and oral antidiabetic drugs occurring at the level of OATP1B1","volume":"41","author":"van de Steeg","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.059105_bib44","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.clpt.6100075","article-title":"Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects","volume":"81","author":"van Giersbergen","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.114.059105_bib45","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1177\/0091270009337514","article-title":"Gender is an important determinant of the disposition of the loop diuretic torasemide","volume":"50","author":"Werner","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.114.059105_bib46","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1248\/bpb1978.4.879","article-title":"A pharmacokinetic analysis program (multi) for microcomputer","volume":"4","author":"Yamaoka","year":"1981","journal-title":"J Pharmacobiodyn"},{"key":"10.1124\/dmd.114.059105_bib47","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1124\/dmd.105.008938","article-title":"Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans","volume":"34","author":"Yamashiro","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.059105_bib48","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/clpt.2011.351","article-title":"Transporter-mediated drug-drug interactions involving OATP substrates: predictions based on in vitro inhibition studies","volume":"91","author":"Yoshida","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.114.059105_bib49","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1146\/annurev-pharmtox-011112-140309","article-title":"Hepatic and intestinal drug transporters: prediction of pharmacokinetic effects caused by drug-drug interactions and genetic polymorphisms","volume":"53","author":"Yoshida","year":"2013","journal-title":"Annu Rev Pharmacol Toxicol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624103480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624103480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.114.059105","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T14:27:52Z","timestamp":1739888872000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624103480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0090955624103480"],"URL":"https:\/\/doi.org\/10.1124\/dmd.114.059105","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725244133.793523469","asserted-by":"object"}]},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigation of the Impact of Substrate Selection on In Vitro Organic Anion Transporting Polypeptide 1B1 Inhibition Profiles for the Prediction of Drug-Drug Interactions","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.114.059105","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2014 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}